secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2021-08-09T23:59:59+00:00
Accession:  0001564590-21-042744
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics hires Lisa Delfini as CFO with $330K base salary and 100,000-share option grant
--------------------------------------------------------------------------------

- Lisa Delfini appointed CFO and principal financial officer, effective August 9, 2021.
- Base salary of $330,000 and annual incentive bonus up to 35% of base.
- Granted option to purchase 100,000 shares vesting over 4 years (25% on first anniversary, then monthly).
- Eligible for separation benefits under Company plan, with modified terms for termination before Aug 9, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000156459021042744/0001564590-21-042744-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000156459021042744/trvi-8k_20210809.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-042744

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer